Regenerative Medical Technology Group(RMTG)
$0.03-0.01 (-22.86%)
RMTG
Regenerative Medical Technology Group financials statements
$0.03
At close:-0.01 (-22.86%)
Want to see RMTG full AI Analyst Report?
Regenerative Medical Technology Group (RMTG) Ratios
6 Followers
Regenerative Medical Technology Group Ratios
RMTG's free cash flow for Q2 2026 was $288.48K. For the 2026 fiscal year, RMTG's free cash flow was decreased by $-43.50K and operating cash flow was $331.97K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.03 | 0.04 | 0.03 | 0.14 | 0.72 |
| Quick Ratio | 0.03 | 0.04 | 0.03 | 0.14 | 0.71 |
| Cash Ratio | 0.03 | 0.04 | 0.02 | 0.14 | 0.71 |
| Solvency Ratio | -0.19 | -0.17 | -0.39 | -0.27 | -0.80 |
| Operating Cash Flow Ratio | -0.02 | 0.03 | -0.02 | -0.09 | -2.34 |
| Short-Term Operating Cash Flow Coverage | -0.04 | 0.05 | -0.03 | -0.16 | -6.47 |
| Net Current Asset Value | $ -38.01M | $ -29.93M | $ -24.10M | $ -18.37M | $ -13.04M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 4.36 | 5.25 | 6.13 | 1.87 | 1.44 |
| Debt-to-Equity Ratio | -0.56 | -0.73 | -0.81 | -1.26 | -1.98 |
| Debt-to-Capital Ratio | -1.29 | -2.74 | -4.26 | 4.79 | 2.02 |
| Long-Term Debt-to-Capital Ratio | -0.07 | -0.09 | -0.13 | -2.06 | 2.33 |
| Financial Leverage Ratio | -0.13 | -0.14 | -0.13 | -0.67 | -1.38 |
| Debt Service Coverage Ratio | -0.00 | 0.01 | -0.14 | -0.09 | -2.38 |
| Interest Coverage Ratio | -0.12 | 0.01 | -0.11 | -0.27 | -3.65 |
| Debt to Market Cap | 31.61 | 56.14 | 194.24 | 65.21 | 4.31 |
| Interest Debt Per Share | 2.14 | 2.05 | 1.94 | 1.60 | 1.40 |
| Net Debt to EBITDA | -222.73 | 62.58 | -5.68 | -13.25 | -1.03 |
| Profitability Margins | |||||
| Gross Profit Margin | 55.11% | 68.73% | 69.53% | 57.31% | 34.29% |
| EBIT Margin | -7.15% | 1.98% | -137.85% | -76.55% | -2317.25% |
| EBITDA Margin | -1.64% | 7.35% | -124.98% | -66.57% | -2307.92% |
| Operating Profit Margin | -17.00% | 1.98% | -29.68% | -77.43% | -2268.34% |
| Pretax Profit Margin | -153.18% | -135.43% | -407.21% | -364.33% | -2942.42% |
| Net Profit Margin | -153.18% | -135.43% | -407.21% | -358.99% | -2942.42% |
| Continuous Operations Profit Margin | -153.18% | -135.43% | -407.21% | -364.33% | -2939.41% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 98.53% | 100.00% |
| EBT Per EBIT | 900.92% | -6852.55% | 1372.10% | 470.53% | 129.72% |
| Return on Assets (ROA) | -174.05% | -145.57% | -340.86% | -67.98% | -138.46% |
| Return on Equity (ROE) | 22.48% | 20.33% | 45.03% | 45.85% | 190.68% |
| Return on Capital Employed (ROCE) | 2.68% | -0.32% | 3.69% | 30.23% | -195.24% |
| Return on Invested Capital (ROIC) | 5.71% | -1.11% | 17.26% | -37.11% | -150.15% |
| Return on Tangible Assets | -284.37% | -280.61% | -1041.15% | -286.00% | -422.65% |
| Earnings Yield | -1261.94% | -1557.60% | -10800.42% | -2366.07% | -415.60% |
| Efficiency Ratios | |||||
| Receivables Turnover | 116.41 | 181.71 | 100.60 | 30.75 | 25.38 |
| Payables Turnover | 6.57 | 1.01 | 1.74 | 2.66 | 1.59 |
| Inventory Turnover | 14.37 | 126.98 | 0.00 | 0.00 | 11.87 |
| Fixed Asset Turnover | 3.42 | 5.65 | 6.66 | 6.95 | 19.11 |
| Asset Turnover | 1.14 | 1.07 | 0.84 | 0.19 | 0.05 |
| Working Capital Turnover Ratio | -0.16 | -0.17 | -0.15 | -0.27 | -0.42 |
| Cash Conversion Cycle | -27.01 | -356.49 | -205.81 | -125.28 | -185.01 |
| Days of Sales Outstanding | 3.14 | 2.01 | 3.63 | 11.87 | 14.38 |
| Days of Inventory Outstanding | 25.39 | 2.87 | 0.00 | 0.00 | 30.75 |
| Days of Payables Outstanding | 55.54 | 361.38 | 209.44 | 137.15 | 230.15 |
| Operating Cycle | 28.53 | 4.88 | 3.63 | 11.87 | 45.14 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.06 | 0.07 | -0.03 | -0.09 | -0.86 |
| Free Cash Flow Per Share | -0.10 | 0.05 | -0.06 | -0.11 | -0.86 |
| Dividend Paid and CapEx Coverage Ratio | -1.17 | 3.95 | -1.09 | -5.61 | -2469666.00 |
| Capital Expenditure Coverage Ratio | -1.17 | 3.95 | -1.09 | -5.61 | -2469666.00 |
| Operating Cash Flow Coverage Ratio | -0.04 | 0.04 | -0.02 | -0.07 | -0.74 |
| Operating Cash Flow to Sales Ratio | -0.14 | 0.21 | -0.17 | -0.73 | -22.56 |
| Free Cash Flow Yield | -211.46% | 177.87% | -885.72% | -565.34% | -318.64% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.08 | -0.06 | -0.01 | -0.04 | -0.24 |
| Price-to-Sales (P/S) Ratio | 0.12 | 0.09 | 0.04 | 0.15 | 7.08 |
| Price-to-Book (P/B) Ratio | -0.02 | -0.01 | -0.00 | -0.02 | -0.46 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.47 | 0.56 | -0.11 | -0.18 | -0.31 |
| Price-to-Operating Cash Flow Ratio | -0.88 | 0.42 | -0.22 | -0.21 | -0.31 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 0.00 | -0.00 | 0.00 | -0.00 |
| Enterprise Value Multiple | -230.14 | 63.77 | -5.71 | -13.48 | -1.34 |
| Enterprise Value | 19.23M | 19.24M | 17.21M | 13.73M | 13.49M |
| EV to EBITDA | -230.14 | 63.77 | -5.71 | -13.48 | -1.34 |
| EV to Sales | 3.77 | 4.68 | 7.14 | 8.97 | 30.82 |
| EV to Free Cash Flow | -14.69 | 30.29 | -21.39 | -10.46 | -1.37 |
| EV to Operating Cash Flow | -27.22 | 22.62 | -41.06 | -12.32 | -1.37 |
| Tangible Book Value Per Share | -2.89 | -2.33 | -1.91 | -1.48 | -1.13 |
| Shareholders’ Equity Per Share | -2.75 | -2.18 | -1.75 | -0.98 | -0.59 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.40 | 0.33 | 0.19 | 0.13 | 0.04 |
| Net Income Per Share | -0.62 | -0.44 | -0.79 | -0.45 | -1.12 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.99 | 1.00 |
| Interest Burden | 21.43 | -68.53 | 2.95 | 4.76 | 1.27 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.63 | 0.58 | 0.66 | 1.04 | 22.62 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.01 | 0.64 |
| Income Quality | 0.09 | -1.33 | 0.04 | 0.20 | 0.77 |
Currency in USD

